Open Access

NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer

  • Authors:
    • Dongyu Jia
    • Jesse Underwood
    • Qiuping Xu
    • Qian Xie
  • View Affiliations

  • Published online on: March 19, 2019     https://doi.org/10.3892/ol.2019.10170
  • Pages: 4914-4920
  • Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Notch signaling is well‑known for its role in regulating cell self‑renewal and differentiation. Within the cancer research field, it has been identified that dysregulated Notch signaling is involved directly with various types of cancer. Although Notch signaling is generally considered as oncogenic, it sometimes acts as a tumor suppressor, highlighting the complexity of the role of Notch in cancer. A number of studies have associated Notch signaling components with ovarian cancer, but the underlying molecular mechanisms are not well‑elucidated. In the present study, the roles of main components of Notch signaling in ovarian cancer were systematically analyzed through large data portals, including Prediction of Clinical Outcomes from Genomic Profiles, Gene Expression across Normal and Tumor tissue, CSIOVDB, Broad Institute Cancer Cell Line Encyclopedia and cBioPortal. Upregulated expression of proteins in the Notch signaling pathway components in ovarian cancer was identified to be generally associated with poor overall and disease‑free survival time, and more advanced cancer stages. In addition, Notch components were enriched in ovarian cancer tissues and cell lines. These results led to a proposed neurogenic locus notch homolog protein (NOTCH)2/NOTCH3/Delta‑like protein 3/Mastermind‑like protein 1/a disintegrin and metalloproteinase domain‑containing protein 17 network. Anticancer drugs, developed to target this network, may have high specificity in treating Notch‑associated ovarian cancer.

References

1 

Siebel C and Lendahl U: Notch signaling in development, tissue homeostasis, and disease. Physiol Rev. 97:1235–1294. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Schwanbeck R, Martini S, Bernoth K and Just U: The Notch signaling pathway: molecular basis of cell context dependency. Eur J Cell Biol. 90:572–581. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Jia D, Tamori Y, Pyrowolakis G and Deng WM: Regulation of broad by the Notch pathway affects timing of follicle cell development. Dev Biol. 392:52–61. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Zacharioudaki E and Bray SJ: Tools and methods for studying Notch signaling in Drosophila melanogaster. Methods. 68:173–182. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Jaleco AC, Neves H, Hooijberg E, Gameiro P, Clode N, Haury M, Henrique D and Parreira L: Differential effects of Notch ligands Delta-1 and Jagged-1 in human lymphoid differentiation. J Exp Med. 194:991–1002. 2001. View Article : Google Scholar : PubMed/NCBI

6 

Lobry C, Oh P, Mansour MR, Look AT and Aifantis I: Notch signaling: Switching an oncogene to a tumor suppressor. Blood. 123:2451–2459. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Radtke F and Raj K: The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nature reviews. Cancer. 3:756–767. 2003.PubMed/NCBI

8 

Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, Wu GS and Wu K: Notch signaling: An emerging therapeutic target for cancer treatment. Cancer Lett. 369:20–27. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Yu S, Liu C, Li L, Tian T, Wang M, Hu Y, Yuan C, Zhang L, Ji C and Ma D: Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia. Lab Invest. 95:157–167. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Nagase H and Nakayama K: γ-Secretase-regulated signaling typified by Notch signaling in the immune system. Curr Stem Cell Res Ther. 8:341–356. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Liang T, Zhu L, Gao W, Gong M, Ren J, Yao H, Wang K and Shi D: Coculture of endothelial progenitor cells and mesenchymal stem cells enhanced their proliferation and angiogenesis through PDGF and Notch signaling. FEBS Open Bio. 7:1722–1736. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Wang M, Wang J, Wang L, Wu L and Xin X: Notch1 expression correlates with tumor differentiation status in ovarian carcinoma. Med Oncol. 27:1329–1335. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Galic V, Shawber CJ, Reeves C, Shah M, Murtomaki A, Wright J, Herzog T, Tong GX and Kitajewski J: NOTCH2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype. Pathol Discov. 1:42013. View Article : Google Scholar : PubMed/NCBI

14 

Hu W, Liu T, Ivan C, Sun Y, Huang J, Mangala LS, Miyake T, Dalton HJ, Pradeep S, Rupaimoole R, et al: Notch3 pathway alterations in ovarian cancer. Cancer Res. 74:3282–3293. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Jung SG, Kwon YD, Song JA, Back MJ, Lee SY, Lee C, Hwang YY and An HJ: Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci. 101:1977–1983. 2010. View Article : Google Scholar : PubMed/NCBI

16 

Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, et al: Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 71:6030–6039. 2011. View Article : Google Scholar : PubMed/NCBI

17 

Riedle S, Kiefel H, Gast D, Bondong S, Wolterink S, Gutwein P and Altevogt P: Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activity. Biochem J. 420:391–402. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al: The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 21:938–945. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Shin G, Kang TW, Yang S, Baek SJ, Jeong YS and Kim SY: GENT: Gene expression database of normal and tumor tissues. Cancer Inform. 10:149–157. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Tan TZ, Yang H, Ye J, Low J, Choolani M, Tan DS, Thiery JP and Huang RY: CSIOVDB: A microarray gene expression database of epithelial ovarian cancer subtype. Oncotarget. 6:43843–43852. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI

23 

Cancer Genome Atlas Research N: Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Taylor AB and MacKinnon DP: Four applications of permutation methods to testing a single-mediator model. Behavi Res Methods. 44:806–844. 2012. View Article : Google Scholar

26 

Simes RJ: An improved bonferroni procedure for multiple tests of significance. Biometrika. 73:751–754. 1986. View Article : Google Scholar

27 

Ismail E and Kornovski Y: Surgical staging of ovarian cancer (I FIGO STAGE): IGCS-0018 ovarian cancer. Int J Gynecol Cancer. 25 Suppl 1:S522015. View Article : Google Scholar

28 

Ismail E and Kornovski Y: Advanced stage of epithelial ovarian cancer (ii-iv figo stage). The role of lymph node dissection: IGCS-0019 ovarian cancer. Int J Gynecol Cancer. 25 Suppl 1:S532015. View Article : Google Scholar

29 

Javadi S, Ganeshan DM, Qayyum A, Iyer RB and Bhosale P: Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR Am J Roentgenol. 206:1351–1360. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Gil-Garcia B and Baladron V: The complex role of NOTCH receptors and their ligands in the development of hepatoblastoma, cholangiocarcinoma and hepatocellular carcinoma. Biol Cell. 108:29–40. 2016. View Article : Google Scholar : PubMed/NCBI

31 

Borggrefe T, Lauth M, Zwijsen A, Huylebroeck D, Oswald F and Giaimo BD: The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFbeta/BMP and hypoxia pathways. Biochim Biophys Acta. 1863:303–313. 2016. View Article : Google Scholar : PubMed/NCBI

32 

Wu L and Griffin JD: Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin Cancer Biol. 14:348–356. 2004. View Article : Google Scholar : PubMed/NCBI

33 

Gao MQ, Choi YP, Kang S, Youn JH and Cho NH: CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 29:2672–2680. 2010. View Article : Google Scholar : PubMed/NCBI

34 

Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, et al: Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 21:2084–2095. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Zhu PC, Aliabadi HM, Uludag H and Han J: Identification of potential drug targets in cancer signaling pathways using stochastic logical models. Sci Rep Uk. 6:230782016. View Article : Google Scholar

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jia, D., Underwood, J., Xu, Q., & Xie, Q. (2019). NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer. Oncology Letters, 17, 4914-4920. https://doi.org/10.3892/ol.2019.10170
MLA
Jia, D., Underwood, J., Xu, Q., Xie, Q."NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer". Oncology Letters 17.6 (2019): 4914-4920.
Chicago
Jia, D., Underwood, J., Xu, Q., Xie, Q."NOTCH2/NOTCH3/DLL3/MAML1/ADAM17 signaling network is associated with ovarian cancer". Oncology Letters 17, no. 6 (2019): 4914-4920. https://doi.org/10.3892/ol.2019.10170